Pediatric genitourinary tumors

Current Opinion in Oncology

Volumn 11, Issue 3, 1999, Pages 218-225

  Lee, Helen H K ^a   Farhat, Walid ^a   Prasad, Alpana ^a   Alabdul Aaly, Mohamad ^a   Merguerian, Paul A ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DACTINOMYCIN; DOXORUBICIN; METHOTREXATE; PHYTIC ACID; VINCRISTINE;

CANCER STAGING; CHILDHOOD CANCER; CLINICAL FEATURE; CLINICAL TRIAL; HUMAN; NEPHROBLASTOMA; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA; TESTIS TUMOR; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; UROGENITAL TRACT TUMOR;

CHILD; HUMANS; INCIDENCE; KIDNEY NEOPLASMS; MALE; NEOPLASM STAGING; RHABDOMYOSARCOMA; TESTICULAR NEOPLASMS; UROGENITAL NEOPLASMS; WILMS TUMOR;

EID: 0032892734     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199905000-00015     Document Type: Review

References (57)

1. Paulino AC, Thakkar B, Henderson WG: Metachronous bilateral Wilms' tumor: the importance of time interval to the development of a second tumor. Cancer 1998, 82:415-420. The authors discuss the prognostic significance of the time interval to development of a contralateral WT and the issue of how long to screen the contralateral kidney.
2. Fear NT, Roman E, Reeves G, Pannett B: Childhood cancer and paternal employment in agriculture: the role of pesticides. Br J Cancer 1998, 77:825-829
3. Menke A, McInnes L, Hastie ND, Schedl A: The Wilms' tumor suppressor WT1: approaches to gene function. Kidney Int 1998, 53:1512-1518
4. Duarte A, Caricasole A, Graham CF, Ward A: Wilms' tumour-suppressor protein isoforms have opposite effects on Igf2 expression in primary embryonic cells, independently of p53 genotype. Br J Cancer 1998, 77:253-259
5. Maheswaran S, Englert C, Lee SB, Ezzel RM, Settleman J, Haber DA: E1B 55K sequesters WT1 along with p53 within a cytoplasmic body in adenovirus-transformed kidney cells. Oncogene 1998, 16:2041-2050
6. Dehbi M, Hiscott J, Pelletier J: Actication of the wt1 Wilms' tumor suppressor gene by NF-κB. Oncogene 1998, 16:2033-2039
7. Karnik P, Chen P, Paris M, Yeger H, Williams BR: Loss of heterozygosity at chromosome 11p15 in Wilms tumors: identification of two independent regions. Oncogene 1998, 17:237-240. The authors have refined the locus of WT2 within chromosome 11p15.5 and have identified a novel locus on 11p15 that may be involved in WT.
8. Crider-Miller SJ, Reid LH, Higgins MJ, Nowak NJ, Shows TB, Futreal PA, Weissman BE: Novel transcribed sequences within the BWS/WT2 region in 11p15.5: tissue-specific expression correlates with cancer type. Genomics 1997, 46:355-363
9. Stayner CK, Cunliffe HE, Ward TA, Eccles MR: Cloning and characterization of the human PAX2 promoter. J Biol Chem 1998, 273:25472-25479
10. Fraizer GC, Shimamura R, Zhang X, Saunders GF: PAX 8 regulates human WT1 transcription through a novel DNA binding site. J Biol Chem 1997, 272:30678-30687
11. Grundy RG, Pritchard J, Scambler P, Cowell JK: Loss of heterozygosity for the short arm of chromosome 7 in sporadic Wilms tumor. Oncogene 1998, 395-400. Loss of heterozygosity has been found in a novel chromosomal region, possibly indicating the location of another tumor suppressor gene in WT.
12. McDonald JM, Douglass EC, Fisher R, Geiser CF, Krill CE, Strong LC, et al.: Linkage of familial Wilms' tumor predisposition to chromosome 19 and a two-locus model for the etiology of familial tumors. Cancer Res 1998, 58:1387-1390
13. Charles AK, Brown KW, Berry PJ: Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development. Am J Pathol 1998, 153:991-1000
14. Wiener JS, Coppes MJ, Ritchey ML: Current concepts in the biology and management of Wilms tumor. J Urol 1998, 159:1316-1325. An excellent review of the current state of knowledge of the molecular genetics, pathology, and management of WT, including the NWTS-5 treatment protocol.
15. Ohtsuka Y, Takahashi H, Ohnuma H, Tanabe M, Yoshida H, Iwai J: Detection of tumor thrombus in children using color Doppler ultrasonography. J Pediatr Surg 1997, 32:1507-1510
16. Rohrschneider WK, Weirich A, Rieden K, Darge K, Troger J, Graf N: US, CT and MR imaging characteristics of nephroblastomatosis. Pediatr Radiol 1998, 28:435-443. An interesting discussion of the differentiation of nephrogenic rests/nephroblastomatosis from WT using various imaging modalities.
17. DeBaun MR, Tucker MA: Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. J Pediatr 1998, 132:398-400. An informative overview of the relative risks for development of a variety of malignancies in children with Beckwith-Wiedemann syndrome.
18. Beckwith JB: Children at increased risk for Wilms tumor: monitoring issues. J Pediatr 1998, 132:377-379. This editorial addresses several different issues in the cost-benefit analysis for screening certain subgroups of children for WT
19. De Baun MR, Siegel MJ, Choyke PL: Nephromegaly in infancy and early childhood: a risk factor for Wilms tumor in Beckwith-Wiedemann syndrome. J Pediatr 1998, 132:401-404. The authors discuss screening for WT in children with Beckwith-Wiedemann syndrome and the identification of persistent nephromegaly as a risk factor
20. Saba LM, de Camargo B, Gabriel-Arana M: Experience with six children with fetal rhabdomyomatous nephroblastoma: review of the clinical, biologic, and pathologic features. Med Pediatr Oncol 1998, 30:152-155
21. Green DM, Breslow NE, Beckwith JB, Finklestein JZ, Grundy PE, Thomas PRM, et al.: Comparison between single-dose and divided-dose administration fo dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1998, 16:237-245. The results from NWTS-4 are presented, showing that pulse-intensive combination chemotherapy should be the new standard for both low-risk and high-risk WT.
22. Saylors RL III, Stewart CF, Zamboni WC, Wall DA, Bell B, Stine KC, Vietti TJ: Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group study. J Clin Oncol 1998, 16:945-952
23. Maurer K, Heitger A, Schwaighofer H, Fink FM, Niederweiser D: Double high-dose chemotherapy with autologous peripheral stem cell rescue in relapsed Wilms' tumor. Bone Marrow Transplant 1997, 20:1111-1113
24. Dagher R, Kreissman S, Robertson KA, Provisor A, Bergstein J, Burke K, et al.: High dose chemotherapy with autologous peripheral blood progenitor cell transplantation in an anephric child with multiply recurrent Wilms tumor. J Pediatr Hematol Oncol 1998, 20:357-360
25. Godzinski J, Tournade MF, deKraker J, Lemerle J, Voute PA, Weirich A, et al.: Rarity of surgical complications after postchemotherapy nephrectomy for neuroblastoma: experience of the International Society of Paediatric Oncology - Trial and Study "SIOP-9." International Society of Paediatric Oncology Nephroblastoma Trial and Study Committee. Eur J Pediatr Surg 1998, 8:83-86
26. Moorman-Voestermans CG. Aronson DC. Staalman CR, Delemarre JF, de Kraker J: Is partial nephrectomy appropriate treatment for unilateral Wilms' tumor? J Pediatr Surg 1998, 33:165-170
27. Rudin C, Pritchard J, Fernando ON, Duffy PG, Trompeter RS: Renal transplantation in the management of bilateral Wilms' tumour (BWT) and of Denys-Drash syndrome (DDS). Nephrol Dial Transplant 1998, 13:1506-1510
28. Flentje M, Weirich A, Graf N, Potter R, Zimmerman H, Ludwig R: Abdominal irradiation in unilateral nephroblastoma and its impact on local control and survival. Int J Radial Oncol Biol Phys 1998, 40:163-169
29. Pachnis A, Pritchard J, Gaze M, Levitt G, Michalski A: Radiotherapy omitted in the treatment of selected children under 3 years of age with stage III favorable histology Wilms tumor. Med Pediatr Oncol 1998, 150-152
30. Saarinen-Pihkala UM, Wikstrom S, Vettenranta K: Maximal preservation of renal function in patients with bilateral Wilms' tumor: therapeutic strategy of late kidney-sparing surgery and replacement of radiotherapy by high-dose melphalan and stem cell rescue. Bone Marrow Transplant 1998, 22:53-59
31. Smith GR, Thomas PR, Ritchey M, Norkool P: Long-term renal function in patients with irradiated bilateral Wilms tumor. National Wilms' Tumor Study Group. Am J Clin Oncol 1998, 21:58-63
32. Prowse OA, Reddy PP, Barrieras D, Jahromi A, Merguerian PA: Pediatric genitourinary tumors. Curr Opin Oncol 1998, 10:253-260
33. Barr FG: Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol 1997, 19:483-491. This review describes the chromosomal translocations in ARMS and the allelic loss at the 11p15 region in ERMS. The subtype-specific and general molecular and genetic alterations in rhabdomyosarcomas and the implications for the pathogenesis and diagnosis of this tumor are discussed.
34. Frascella E, Rosolen A: Detection of the MyoD1 transcript in rhabdomyosarcoma cell lines and tumor samples by reverse transcription polymerase chain reaction. Am J Pathol 1998, 152:577-583
35. Chen B, Dias P, Jenkins JJ, Savell VH, Parham DM: Methylation alterations of the MyoD1 upstream region are predictive of subclassification of human rhabdomyosarcomas. Am J Pathol 1998, 152:1071-1079
36. Gattenloehner S, Vincent A, Leuschner I, Tzartos S, Hermelink HKM, Kirchner T, Marx A: The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumors. Am J Pathol 1998, 152:437-444
37. Gluer S, Schelp C, Schweinitz DV, Schahn RG: Polysialylated neural cell adhesion molecule in childhood rhabdomyosarcoma. Pediatr Res 1998, 43:145-147
38. Kalebic T, Blakesley V, Slade C, Plasschaert S, Leroith D, Helman LJ: Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R. Int J Cancer 1998, 76:223-227
39. Sabbioni S, Brodano GB, Croce CM, Negrini M: GOK: a gene at 11p15 involved in rhabdomyosarcoma and rhabdoid tumor development. Cancer Res 1997, 57:4493-4497
40. Pappo AS, Shapiro DN: Rhabdomyosarcoma: biology and therapy. Cancer Treat Res 1997, 92:309-339. A good review of the recent advances in molecular biology and cytogenetic analysis of ARMS and ERMS. The authors have summarized the therapeutic considerations in the different clinical groups and discussed the relevant contributions from various multi-institutional cooperative trials
41. Coffin CM, Rulon J, Smith L, Bruggers C, White FV: Pathologic features of rhabdomyosarcoma before and after treatment: a clinicopathologic and immunohistochemical analysis. Mod Pathol 1997, 10:1175-1187. The authors have analyzed 16 rhabdomyosarcomas pretreatment and post-treatment for the relationship between pathology, treatment-induced changes, proliferative activity, and outcome
42. Boulad F, Kernan NA, LaQuaglia MP, Heller G, Lindsley KL, Rosenfeld NS, et al.: High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma. J Clin Oncol 1998, 16:1697-1706
43. Nitschke R, Parkhurst J, Sullivan J, Harris MB, Bernstein M, Pratt C: Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 1998, 20:315-318
44. Vucenik I, Kalebic T, Tantivejkul K, Shamsuddin AM: Novel anticancer function of inositol hexaphosphate: inhibition of human rhabdomyosarcoma in vitro and in vivo. Anticancer Res 1998, 18:1377-1384
45. Pappo AS, Bowman LC, Furman WL, Rao BN, Kun LE, Jenkins JJ, et al.: A phase II trial of high-dose methotrexate in previously untreated children and adolescents with high-risk unresectable or metastatic rhabdomyosarcoma. J Pediatr Hematol Oncol 1997, 19:438-442
46. Lombardi F, Navarria P, Gandola L: The evolving role of radiation therapy in the optimal multimodality treatment of childhood cancer. Tumori 1998, 84:270-273. The authors have highlighted the contribution of RT in the high cure rates now reported with rhabdomyosarcoma, WT, and neuroblastoma
47. Merchant TE, Zelefsky MJ, Sheldon JM, LaQuaglia MB, Harnson LB: High-dose rate intraoperative radiation therapy for pediatric solid tumors. Med Pediatr Oncol 1998, 30:34-39
48. Merchant TE, Cahill JC, Ghavimi F: Results of alternating chemotherapy and hyperfractionated radiation therapy in childhood rhabdomyosarcoma. Med Pediatr Oncol 1998, 30:332-338
49. Merguerian PA, Agarwal S, Greenberg M, Bagli DJ, Khoury AE, McLorie GA: Outcome analysis of rhabdomyosarcoma of the lower urinary tract. J Urol 1998, 160:1191-1194
50. Furness PD III, Husmann DA, Brock JW III, Steinhardt GF, Bukowski TP, Freedman AL, et al.: Multi-institutional study of testicular microlithiasis in childhood: a benign or premalignant condition? J Urol 1998, 160:1151-1154
51. Westergaard T, Andersen PK, Pedersen JB, Frisch M, Olsen JH, Melbye M: Testicular cancer risk and maternal paternity: a population-based cohort study. Br J Cancer 1998, 77:1180-1185
52. Hawkins EP: Germ cell tumors. Am J Pathol 1998, 109(suppl):82-84
53. Young RH, Koelliker DD, Scully RE: Sertoli cell tumors of the testis, not otherwise specified: a clinicopathological analysis of 60 cases. Am J Surg Pathol 1998, 22:709-721
54. Kumar PV: Testicular leukemia relapse: fine needle aspiration findings. Acta Cytol 1998, 42:312-316
55. Rogers E, Teahan S, Gallagher H, Butler MR, Grainger R, McDermott TE, Thornhill JA: The role of orchiectomy in the management of postpubertal cryptorchidism. J Urol 1998, 159:851-854
56. Liu HC, Liang DC, Chen SH, Liu FL, Chang PY, Sheu JC, Wang NL: The stage I yolk sac tumor of testis in children younger than 2 years: chemotherapy or not? Pediatr Hematol Oncol 1998, 15:223-228
57. Herrmann T: Radiation reactions in the gonads. Strahlenther Oncol 1997, 173:493-501